{{Infobox drug
| drug_name = 
| IUPAC_name = 2',3',5'-Tri-''O''-acetyluridine
| image = Uridine triacetate structure.svg
| width = 150
| alt = 
| caption =

<!-- Clinical data -->
| pronounce =
| tradename = Vistogard, Xuriden
| Drugs.com = 
| MedlinePlus = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_US = <!-- A / B / C / D / X / N -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_DE = <!-- Anlage I, II, III -->
| legal_NZ = <!-- Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = Rx-only
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status = <!-- Free text -->
| routes_of_administration = Oral granules

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = Pyrimidine catabolic pathway
| metabolites =
| onset = [[Cmax (pharmacology)|T<sub>max</sub>]] = 2–3 hours
| elimination_half-life = 2–2.5 hours
| duration_of_action =
| excretion = [[Kidney|Renal]]

<!-- Identifiers -->
| CAS_number = 4105-38-8
| ATCvet = 
| ATC_prefix = A16
| ATC_suffix = AX13
| PubChem = 20058
| ChemSpiderID = 18897
| DrugBank = DB09144
| KEGG = D09985
| UNII = 2WP61F175M

<!-- Chemical data -->
| chemical_formula =
| C=15 | H=18 | N=2 | O=9
| molecular_weight =
| SMILES = CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n2ccc(=O)[nH]c2=O)OC(=O)C)OC(=O)C
| StdInChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1
| StdInChIKey = AUFUWRKPQLGTGF-FMKGYKFTSA-N
}}

'''Uridine triacetate''' ([[International nonproprietary name|INN]]),<ref name="INN">{{cite web|title=International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65|url=http://www.who.int/medicines/publications/druginformation/innlists/RL65.pdf|publisher=World Health Organization|accessdate=12 March 2017|page=92}}</ref> formerly known as '''vistonuridine''', is an orally active tri-[[Acetylation|acetylated]] [[prodrug]] of [[uridine]]<ref name="DrugBank">{{cite web|title=Uridine triacetate — DrugBank Page|url=https://www.drugbank.ca/drugs/DB09144|date=12 March 2017}}</ref> used:
* in the treatment of hereditary [[orotic aciduria]] (brand name '''Xuriden''' {{IPAc-en|ˈ|z|ʊər|ə|d|ɛ|n}} {{respell|ZOOR|ə|den}});<ref name="Xuriden PI">{{cite web|title=Xuriden (uridine triacetate) Oral Granules. Full Prescribing Information|url=http://www.xuriden.com/FPI.pdf|publisher=Wellstat Therapeutics Corporation. Gaithersburg, MD 20878|accessdate=12 March 2017}}</ref>
* to treat patients following an overdose of [[Chemotherapy|chemotherapy drugs]] [[Fluorouracil|5-fluorouracil]] (5-FU) or [[capecitabine]] regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name '''Vistogard''').<ref name="Vistogard PI">{{cite web|title=Vistogard (uridine triacetate) Oral Granules. Full Prescribing Information|url=https://www.vistogard.com/Vistogard/media/Main-Media/final-labeling-text-vistogard.pdf|publisher=Wellstat Therapeutics Corporation. Gaithersburg, MD 20878|accessdate=12 March 2017}}</ref><ref>{{cite news|title=BTG Announces FDA Approval of Vistogard<sup>®</sup> (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine|url=https://www.btgplc.com/media/press-releases/btg-announces-fda-approval-of-vistogard/|accessdate=12 March 2017|publisher=BTG International Ltd.|date=11 December 2015}}</ref><ref>{{cite web|title=Approved Drugs — Uridine Triacetate|url=https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm476930.htm|publisher=U.S. Food and Drug Administration|accessdate=12 March 2017|language=en}}</ref>

Uridine triacetate was developed, manufactured and distributed by [[Wellstat Therapeutics]] and it is marketed in USA by [[BTG plc|BTG]]. Also, It was granted [[Breakthrough therapy|breakthrough therapy designation]] by FDA in 2015.

==References==
{{reflist|2}}

==External links==
* [http://www.xuriden.com Xuriden Web Page]
* [https://www.vistogard.com Vistogard Web Page]

{{Other alimentary tract and metabolism products}}

[[Category:Antidotes]]
[[Category:Acetate esters]]
[[Category:Prodrugs]]

{{gastrointestinal-drug-stub}}